Abstract
CRISPR-Cas nucleases are transforming genome editing, RNA editing, and diagnostics but have been limited to RNA-guided systems. We present ΨDNA, a DNA-based guide for Cas12 enzymes, engineered for specific and efficient RNA targeting. ΨDNA mimics a crRNA but with a reverse orientation, enabling stable Cas12-RNA assembly and activating trans-cleavage without RNA components. ΨDNAs are effective in sensing short and long RNAs and demonstrated 100% accuracy for detecting HCV RNA in clinical samples. We discovered that ΨDNAs can guide certain Cas12 enzymes for RNA targeting in cells, enhancing mRNA degradation via ribosome stalling and enabling multiplex knockdown of multiple RNA transcripts. This study establishes ΨDNA as a robust alternative to RNA guides, augmenting the potential of CRISPR-Cas12 for diagnostic applications and targeted RNA modulation in cellular environments.
Competing Interest Statement
C.O., S.R.R., and P.K.J., are listed as inventors on a patent application related to the content of this work. P.K.J. is a co-founder of CasNx, Par Biosciences, and CRISPR, LLC. The remaining authors declare no competing interests.
Funding Statement
This work was funded by the University of Florida, the UF Herbert Wertheim College of Engineering, the Shah Foundation Endowment Funds, NIH-NIAID (R21AI156321, R21AI168795, and R61AI181016), and NIH-NIGMS (R35GM147788). The funding sources had no role in study design, data collection, analysis, interpretation, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and processing of patient samples were approved by the University of Florida Institutional Review Board (IRB202200294)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data supporting the findings of this study are provided within the Article and Supplementary Files. Additional data may be obtained from the corresponding author, P.K.J., upon reasonable request.
